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Although the glycoprotein (GP) Ib-IX-V complex and
FcgRIIA are distinct platelet membrane receptors, pre-
vious studies have suggested that these structures may
be co-localized. To determine more directly the proxim-
ity of GP Ib-IX-V and FcgRIIA, we assessed the effects of
anti-GP Iba monoclonal antibodies on FcgRIIA-medi-
ated platelet aggregation and on the direct binding of
polymeric IgG to human platelets. In addition, we di-
rectly examined the proximity of FcgRII and GP Ib-IX-V
using flow cytometric fluorescence energy transfer and
immunoprecipitation studies. Preincubation of plate-
lets with either of two monoclonal antibodies (AN51 or
SZ2) directed against GP Iba completely blocked plate-
let aggregation by polymeric IgG. Similarly, these anti-
bodies totally inhibited platelet aggregation by two
strains of viridans group streptococci known to induce
aggregation via FcgRIIA. In addition, AN51 and SZ2 sig-
nificantly reduced the binding of polymeric IgG to
washed fixed platelets. When assessed by flow cytom-
etry, significant levels of bidirectional energy transfer
were detected between FcgRIIA and GP Iba, indicating
a physical proximity of less than 10 nm between these
receptors. This energy transfer was not due to high re-
ceptor density, because no homoassociative energy
transfer was seen. Moreover, immunoprecipitation of
FcgRIIA from platelet lysates also co-precipitated GP
Iba. These results indicate that GP Iba and FcgRIIA are
co-localized on the platelet membrane and that this as-
sociation is not random.
The glycoprotein (GP)1 Ib-IX-V complex and FcgRIIA are
distinct platelet membrane receptors for von Willebrand factor
and polymeric IgG, respectively. The GP Ib-IX-V complex con-
tains four polypeptides (GP Iba, GP Ibb, GP IX, and GP V),
which are present in a stoichiometry of 2:2:2:1 on the platelet
plasma membrane (1). The precise configuration by which
these peptides form a functional receptor is unknown, although
more than one copy of each polypeptide per receptor complex is
probable (1). This receptor mediates platelet adhesion to sites
of blood vessel injury by binding von Willebrand factor in the
subendothelium and participates in platelet activation by
thrombin by providing a high affinity binding site for this
agonist. In contrast to the GP Ib-IX-V complex, the platelet
receptor for the Fc portion of IgG, FcgRIIA, is much simpler in
structure, consisting of a single transmembrane polypeptide.
This receptor is responsible for the aggregation and activation
of platelets induced by immune complexes, opsonized bacteria,
and certain antibodies that bind other platelet surface proteins
(2).
Although GP Ib-IX-V and FcgRIIA are structurally unre-
lated, a functional interaction between these receptors has
been suspected for some time. Moore et al. reported that both
polymeric IgG and IgG Fc fragments could inhibit platelet
aggregation induced by von Willebrand factor and ristocetin
(3). The reciprocal phenomenon was also observed, i.e. prior
incubation of platelets with von Willebrand factor and ristoce-
tin inhibited platelet aggregation by polymeric IgG. More re-
cent studies examining heparin-induced platelet aggregation,
which is mediated by anti-heparin antibodies, further suggest
a proximity of GP Ib-IX-V and FcgRIIA. In particular, platelet
aggregation by heparin can be blocked by antibodies directed
against either FcgRIIA or GP Iba (4, 5). Moreover, anti-GP Ib
antibodies inhibit heparin-induced aggregation of platelets ob-
tained from normal donors but not of platelets from individuals
with the Bernard-Soulier syndrome, which lack the GP Ib-IX-V
complex (4).
Although these findings suggest a physical proximity or
functional interaction of FcgRIIA and the GP Ib-IX-V complex,
such an association has never been demonstrated directly. In
the current studies, we used three distinct approaches to de-
termine whether these receptors are physically associated.
First, we assessed whether anti-GP Iba monoclonal antibodies
would affect either FcgRIIA-mediated platelet aggregation (in-
duced by polymeric IgG or antibody-coated bacteria) or the
direct binding of polymeric IgG to human platelets. Second, we
directly examined the proximity of FcgRIIA and GP Ib-IX-V on
the platelet membrane as measured by flow cytometric fluores-
cence energy transfer. Third, we assessed by co-immunopre-
cipitation experiments whether these receptors were linked
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covalently. As discussed below, these studies strongly indicate
that GP Ib-IX-V and FcgRIIA are co-localized on the platelet
membrane and that these receptors may be functionally
interactive.
EXPERIMENTAL PROCEDURES
Polymeric IgG—Polymeric IgG was produced either by heating or
chemically cross-linking an IgG solution. For the former procedure, IgG
was purified from human immunoglobulin (Miles Laboratory, Elkhart,
IN) by protein A affinity chromatography. IgG aggregates were gener-
ated by heating a 2 mg/ml solution of the purified IgG in phosphate-
buffered saline at 63 °C for 30 min (6). Macroscopic aggregates were
removed by centrifugation (12,000 3 g, 10 min), and the protein content
of the supernatant was determined using a bicinchoninic acid assay
(Pierce) (7). To produce chemically cross-linked IgG (8), a 100 mg/ml
solution of purified human IgG1 (Sigma) in 0.1 M Tris buffer (pH 8.5)
was treated with a 10-fold molar excess of dimethyl suberimidate for 2 h
at 30 °C followed by dialysis, centrifugation, and determination of its
protein content.
Monoclonal Antibodies—The following monoclonal antibodies (mAb),
both unlabeled and conjugated with FITC, were obtained from commer-
cial sources: mAb AN51 (anti-GP Iba; Immunotech International, West-
brook, ME); mAb SZ2 (anti-GP Iba; DAKO, Carpinteria, CA); mAb
FA6.152 (anti-CD36, Immunotech). mAb WM23 (anti-GP Iba) was a gift
from Dr. Michael Berndt of the Baker Research Institute, Prahran,
Victoria, Australia. mAb IV.3 (anti-FcgRII) was purchased from
Mederex (West Lebanon, NH) or purified from the ascites of BALB/c
mice inoculated with hybridoma IV.3 (American Type Culture Collec-
tion, Rockville, MD) using ammonium sulfate precipitation (9) and
protein G affinity chromatography as recommended by the manufac-
turer (Pharmacia Biotech Inc.). Antibodies were conjugated with cya-
nine 3.18 (Cy3) using the Fluorolink-Ab Cy3 labeling kit as per the
manufacturer’s instructions (Biological Detection Systems, Pittsburgh,
PA). Labeling of the mAbs with FITC or Cy3 had no effect on binding
affinity as measured by a previously described competitive assay (10).
Preparation of Human Platelets—Platelet-rich plasma (PRP) and
washed platelets were prepared from freshly obtained human blood as
described previously (11). To produce PRP, blood was collected in tubes
containing 3.8% buffered citrate solution (anticoagulant-to-blood ratio,
1:9) and centrifuged (100 3 g, 15 min, 25 °C) to remove erythrocytes
and leukocytes. PRP was recovered by collecting the uppermost two-
thirds of the top layer.
Washed platelets were produced by collecting 5 volumes of blood into
a syringe containing 1 volume of acid-citrate-dextrose (85 mM Na cit-
rate, 111 mM glucose, 71 mM citric acid) anticoagulant and prosta-
glandin I2 (final concentration, 1 mg/ml; Sigma). The platelets were then
washed three times in 140 mM NaCl, 20 mM HEPES, 6 mM glucose, 1
mM EDTA, pH 6.6, and then suspended in Tyrode’s salt solution (TSS,
Sigma) pH 7.2 (11). For flow cytometry, washed platelets were fixed in
0.8% paraformaldehyde (12), washed, and suspended in TSS. Platelets
prepared by this technique were not activated, as shown by minimal
expression of surface P-selectin (13), when measured by flow cytometry
(data not shown).
Preparation of Bacteria for Aggregometry—Streptococcus sanguis
strain M99 and S. salivarius strain D1 previously have been shown to
induce platelet aggregation via FcgRIIA (14). To produce bacterial
suspensions for platelet aggregometry, each strain was grown for 18 h
at 37 °C in Todd-Hewitt broth and then washed, sonicated, and sus-
pended in TSS as described (11). The concentrations of organisms were
determined by counting in a hemacytometer and adjusted to 3 3 109
bacteria/ml by the addition of TSS.
Platelet Aggregometry—The ability of polymeric IgG or bacteria to
aggregate platelets was tested by conventional light aggregometry us-
ing a single-channel aggregometer (Model 330, Chronolog, Haverton,
PA). For polymeric IgG, 50 ml of a 10 mg/ml stock solution was added to
450 ml of washed platelets (3 3 108/ml) suspended in TSS. To assess
platelet aggregation by streptococci, washed bacteria suspended in TSS
were added to PRP at a final bacterium/platelet ratio of 1:1. Platelet
aggregation was analyzed with regard to the time interval between the
addition of an agonist to the platelet suspension and the onset of
aggregation (lag phase), the rate of aggregation (slope at the midpoint
of aggregation), and the maximum change in light transmission. All
agonists were tested on multiple occasions using platelets from differ-
ent donors. Human thrombin (1 unit/ml), ADP (10 mM), or ristocetin (1
mg/ml) served as controls for a positive aggregation response (all re-
agents from Sigma).
Binding of Polymeric IgG to Human Platelets—The binding of poly-
meric IgG to human platelets was assessed by flow cytometry. Washed
fixed platelets (1 3 108/ml) suspended in TSS containing 1% bovine
serum albumin were incubated with 1 mg/ml polymeric IgG for 1 h at
4 °C. After three washings in TSS, the platelets were incubated with 1.5
mg/ml FITC-conjugated goat anti-human F(ab9)2 IgG (Caltag, South
San Francisco, CA). Platelets were diluted 500-fold, and 10,000 cells/
sample were analyzed by flow cytometry using a Becton Dickinson
FACScan (San Jose, CA). The threshold for forward scatter was set to
eliminate small debris and gated to omit cell doublets and clumps. IgG
binding was detected as the mean log FITC fluorescence emission in the
Fl1 channel using a 530 6 30 nm band-pass filter. Platelets incubated
with secondary antibody alone served as controls for nonspecific bind-
ing. To determine the relative ability of the monoclonal antibodies to
inhibit polymeric IgG binding, fixed platelets were incubated for 1 h
with 10 mg/ml of mAb IV.3, mAb AN51, or mAb SZ2. After washing
twice in TSS, the binding of polymeric IgG was assessed by flow cytom-
etry as described above.
Fluorescence Resonance Energy Transfer—To assess directly the
proximity of the FcgRIIA receptor and the GP Ib-IX-V complex on the
cell surface, the efficiency of fluorescence energy transfer (FET) be-
tween FITC-labeled monoclonal antibodies (donor) and CY3-conjugated
monoclonal antibodies (acceptor) was measured by flow cytometry as
described previously (10, 15, 16). A FACStar Plus flow cytometer
(Becton Dickinson) with dual-laser excitation (488 and 528 nm) was
used to determine platelet surface FET measurements. For each sample
analyzed, at least 20,000 events were collected. Using threshold set-
tings and light-scatter gating as described above, five intensities were
measured on a cell-by-cell basis: (i) forward scattered light at 488 nm;
(ii) orthogonal scattered light at 488 nm; (iii) fluorescence emission at
510 6 15 nm, when excited at 488 nm; (iv) fluorescence emission at
.580 nm, when excited at 528 nm; (v) fluorescence emission at .580
nm, when excited at 488 nm (representing energy transfer from FITC to
Cy3). The contribution of autofluorescence was determined using unla-
beled platelets. To calculate FET efficiency for dual-labeled cells on a
cell-by-cell basis, correction factors for spectral overlap were deter-
mined from single-labeled platelets.
The calculated transfer efficiency was expressed as the percentage of
the excitation energy taken up by the donor (FITC) and transferred to
the acceptor (Cy3). This method can accurately detect proximity in the
2–10 nm range (17, 18). Factors that influence efficiency of transfer
include the proximity of the donor and acceptor dyes and the concen-
tration of acceptor molecules. To control for the possible influence of a
high concentration of acceptor molecules, each pair of epitopes meas-
ured was cross-checked by its inverse fluorochrome set (e.g. FITC-IV.3/
CY3-SZ2 was checked by CY3-IV.3/FITC-SZ2). To better define a spe-
cific signal in mAb IV.3-labeled cells, further gating on the list mode
data was made to select the brightest 10% of cells. After correction for
autofluorescence and spectral overlap, energy transfer efficiencies were
calculated as described previously (10, 19).
To confirm that energy transfer between GP Ib-IX-V and FcgRIIA
was due to receptor co-localization and not an artifact of high receptor
density or coincidental association, we then assessed each epitope
bound by the above mAbs for homoassociation (20). Platelets were
dual-labeled as described above with (i) FITC-labeled IV.3 paired with
Cy3-labeled IV.3, (ii) FITC-labeled AN51 paired with Cy3-labeled
AN51, and (iii) FITC-labeled SZ2 paired with Cy3-labeled SZ2. After
washing, platelets were analyzed by flow cytometry for evidence of
energy transfer.
Immunoprecipitation and Western Blotting—Blood from healthy do-
nors was drawn into acid-citrate-dextrose buffer containing prosta-
glandin I2, and PRP was prepared as described above. Immunoprecipi-
tation studies were performed with and without the use of a chemical
cross-linking reagent. For the former, 100 ml of PRP were incubated in
2 mmol of dithiobis(sulfosuccinimidylpropionate) (DTSSP, Pierce, Rock-
ford, IL) for 30 min at room temperature, followed by lysis in buffer
containing 1% digitonin and a mixture of protease inhibitors (20 mg/ml
leupeptin, 1.6 mg/ml benzamidine, 1 mg/ml soybean trypsin inhibitor,
and 1 mM phenylmethylsulfonyl fluoride). For the latter, identical ali-
quots of PRP were lysed directly without prior treatment with DTSSP.
FcgRIIA was immunoprecipitated from the platelet lysate with mAb
IV.3 using fixed Staphylococcus aureus cells (Pansorbin beads, Calbio-
chem). The lysate was first incubated overnight with Pansorbin at 4 °C
to remove proteins that bound nonspecifically to the beads. After re-
moving the Pansorbin by centrifugation, mAb IV.3 was added to the
lysate to a final concentration of 2.6 mg/ml and incubated for 4 h at 4 °C
with rocking. The platelet lysates were then incubated with rabbit
anti-mouse IgG secondary antibody (5 mg/ml) (Zymed, San Francisco,
CA) for a further 1 h at 4 °C. Pansorbin beads were then added to the
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lysate and incubated for 1 h at 4 °C. The beads were removed by
centrifugation at 10,000 3 g for 5 min and then resuspended and
washed twice in lysis buffer. Bound protein was removed from the beads
by boiling in SDS sample buffer containing 2% b-mercaptoethanol.
Solubilized proteins were electrophoresed on 7.5% SDS-polyacryl-
amide gels and transferred to nitrocellulose membranes. Nonspecific
protein binding sites on the membrane were blocked by incubation in
Tris-buffered saline, pH 7.4, containing 0.2% Tween 20 and 5% nonfat
milk for 60 min at room temperature. Co-immunoprecipitated GP Iba
was detected by incubating the membrane with mAb WM23 (0.2 mg/ml)
for 60 min at room temperature followed by a further 45 min of incu-
bation with horseradish peroxidase-conjugated sheep anti-mouse IgG.
After washing the membrane thoroughly, bound antibody was detected
using a commercial chemiluminescence kit (ECL kit, Amersham Corp.)
according to the manufacturer’s instructions.
Statistical Analysis—Mean values were compared by the unpaired t
test using analysis of variance and the Bonferroni correction for mul-
tiple comparisons.
RESULTS
Effects of mAbs on Platelet Aggregation by Polymeric IgG—
Addition of 1 mg/ml of polymeric IgG to washed platelets re-
sulted in a lag phase of 6.5 6 5.3 min (mean 6 S.D.) followed by
irreversible platelet aggregation (n 5 18) (Fig. 1A). As ex-
pected, this aggregation was blocked completely by 100 ng/ml
mAb IV.3 (6). In addition, platelet aggregation by polymeric
IgG was completely inhibited both by mAb AN51 and mAb SZ2,
when either mAb was tested at 10 mg/ml (n 5 5; Fig. 1B). At 1
mg/ml, the effects of these mAbs were variable, with aggrega-
tion being either partially inhibited (prolonged lag phase, de-
creased maximal change in optical transmission) or blocked
completely. In control studies, washed platelets treated with
SZ2, AN51, or IV.3 aggregated normally in response to throm-
bin (1 unit/ml), whereas FA6.152 (anti-CD36) had no effect on
platelet aggregation induced by polymeric IgG, indicating that
inhibition by the above mAbs was relatively specific.
Effects of mAbs on Platelet Aggregation by Viridans Group
Streptococci—Platelet aggregation by many strains of viridans
group streptococci requires opsonization of bacteria with spe-
cific IgG followed by platelet activation via FcgRIIA (11, 14,
21). To confirm that FcgRIIA-mediated platelet aggregation
could be inhibited by mAbs to GP Iba, we examined the effects
of mAbs SZ2 and AN51 on platelet aggregation by two strains
of viridans group streptococci. Addition of S. sanguis strain
M99 or S. salivarius strain D1 to PRP resulted in mean lag
phases of 9.5 6 2.2 and 11.3 6 5.1 min, respectively, followed
by rapid and irreversible platelet aggregation (n 5 5; Fig. 1C).
FIG. 1. Inhibition of FcgRIIA-mediated platelet aggregation by anti-GP Ia mAbs. A, addition of polymeric IgG to washed platelets
resulting in a lag phase of 10 min followed by aggregation. B, pretreatment of platelets with AN51(10 mg/ml) completely blocked subsequent
aggregation by polymeric IgG. C, aggregation of platelets by S. sanguis strain M99. D, complete inhibition by mAb SZ2 (10 mg/ml) of M99-induced
platelet aggregation.
FIG. 2. Inhibition of polymeric IgG binding to human platelets
by anti-GP Ia mAbs. Binding of polymeric IgG to platelets was meas-
ured by flow cytometry using an FITC-conjugated goat anti-human IgG
secondary antibody. A, platelets alone. B, platelets incubated with
polymeric IgG. C, platelets pretreated with mAb IV.3 prior to incuba-
tion with polymeric IgG. D, platelets pretreated with mAb SZ2 before
incubation with polymeric IgG.
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As with aggregation induced by polymeric IgG, preincubation
of the platelets with mAb IV.3 (100 ng/ml) completely blocked
aggregation by these organisms. In addition, platelet aggrega-
tion by streptococci was also blocked by 10 mg/ml mAb SZ2 or
mAb AN51 (n 5 4; Fig. 1D). Inhibition by these mAbs was
selective; ADP normally aggregated platelets pretreated with
IV.3, AN51, or SZ2. Moreover, FA6.152 failed to block platelet
aggregation by either strain M99 or D1, indicating that the
inhibition by mAbs directed against platelet GP Iba was not
merely due to a nonspecific or generalized effect of antibody
binding to the platelet surface.
Inhibition of Polymeric IgG Binding to Platelets—We then
examined whether mAbs AN51 and SZ2 inhibited aggregation
by reducing binding of polymeric IgG to the platelets. As shown
in Fig. 2, the binding of polymeric IgG to washed fixed platelets
could be readily detected by flow cytometry. When probed with
FITC-conjugated goat anti-human F(ab9)2, platelets incubated
with polymeric IgG appeared as a discrete population clearly
separated from platelets treated with secondary antibody
alone. Preincubation of platelets with IV.3 reduced binding by
98.8 6 21.1% (mean 6 S.D., n 5 8, p , 0.01), indicating that
binding by polymeric IgG to platelets was predominantly me-
diated by FcgRIIA (Fig. 2C). Preincubation of platelets with 10
mg/ml of SZ2 or AN51 also reduced binding significantly, by
98.1 6 19.8% (p , 0.01) and 73.0 6 19.9% (p , 0.05), respec-
tively (Fig. 2D; n 5 5). In control studies, platelets pretreated
with anti-CD36 had levels of polymeric IgG binding compara-
ble to those seen with untreated platelets (data not shown).
Analysis of Receptor Co-localization by Fluorescence Energy
Transfer—The above results indicated that FcgRIIA and GP
Ib-IX-V are in physical proximity on the platelet membrane. To
examine more definitively the potential co-localization of these
receptors, we measured FET between labeled mAbs directed
against epitopes on each receptor (Fig. 3). As expected, the two
epitopes on GP Ib-IX-V bound by AN51 and SZ2 showed sig-
nificant levels of FET (Table I). For example, percent energy
transfer from FITC-labeled AN51 to Cy3-labeled SZ2 was
16.3 6 3.9%. Comparable levels of energy transfer were ob-
served with FITC-labeled SZ2 paired with Cy3-labeled AN51.
FET measurements between FcgRIIA and GP Ib-IX-V also
indicated significant proximity between these receptors. For
example, the mean energy transfer from FITC-labeled AN51 to
Cy3-labeled IV.3 was 9.2 6 3.2% (p , 0.001, compared with
single-labeled controls). Comparable levels of FET were ob-
served between these epitopes when the donor and acceptor
dyes were reversed (FITC-labeled IV.3 and Cy3-labeled AN51).
Significant FET was also seen between FITC-labeled IV.3 and
Cy3-SZ2 (6.8 6 3.0) as well as between these epitopes when the
fluorochrome labels were reversed (5.2 6 1.4; p , 0.01).
Energy transfer between two different receptors may be due
to true co-localization or may result from a high surface density
of receptors, which would result in FET because of crowding on
the platelet surface (19). To determine whether the observed
FET was due to high receptor density (as opposed to true
co-localization), we then examined the epitopes bound by mAbs
AN51, SZ2, and IV.3 for homoassociation. No evidence of sig-
nificant FET was detected for any of the three antibody pairs
tested, indicating that neither FcgRIIA nor GP Iba was ex-
pressed at a density sufficient to produce FET via chance
transfer.
Physical Association between the GP Ib-IX-V Complex and
FcgRIIA—As another means of studying the association of the
two receptors, we attempted to co-immunoprecipitate GP Ib-
IX-V complex with FcgRIIA using mAb IV.3 and digitonin
lysates of platelets. These experiments were performed with or
without pretreatment of the platelets with the bifunctional
cross-linking agent DTSSP. When tested with lysates of un-
treated platelets, mAb IV.3 co-precipitated GP Iba in parallel
with FcgRIIA, but with considerable variation in the amount of
GP Iba recovered on repeated testing. However, pretreatment
of platelets with DTSSP resulted in the consistent co-precipi-
tation of GP Iba with FcgRIIA in quantities comparable to
those obtained with antibodies against GP V or GP Iba itself
(Fig. 4).
DISCUSSION
Although GP Ib-IX-V and FcgRIIA are seemingly unrelated
receptors on the platelet membrane, previous reports had sug-
gested a functional cooperation or structural association of
these surface structures. With this study, we provide strong
evidence that the functional interaction between GP Ib-IX-V
and FcgRIIA is largely due to a direct physical interaction.
Several observations support this conclusion. First, we found
that mAbs to GP Iba completely blocked platelet aggregation
induced by polymeric IgG, which is an FcgRIIA-mediated proc-
ess. These antibodies apparently inhibited aggregation by
blocking the binding of polymeric IgG to FcgRIIA. Indeed, we
TABLE I
Fluorescence energy transfer
Fluorescence energy transfer efficiency values between platelet mem-
brane epitopes using monoclonal antibodies to glycoprotein Iba (AN51
and SZ2) and FcgRII (IV.3). Energy transfer was measured between
FITC-labeled (donor) and Cy3-labeled (acceptor) epitopes by flow cy-
tometry. n 5 6 experiments.
Donor (FITC) Acceptor (Cy3) Energy transfer(mean 6 S.D.) p value
%
AN51 SZ2 16.3 6 3.9 ,0.001
SZ2 AN51 23.6 6 5.7 ,0.001
AN51 IV.3 9.2 6 3.2 ,0.001
IV.3 AN51 5.2 6 2.9 ,0.01
SZ2 IV.3 5.2 6 1.4 ,0.01
IV.3 SZ2 6.7 6 3.0 ,0.001
IV.3 IV.3 1.7 6 0.9 .0.05
AN51 AN51 1.9 6 1.1 .0.05
SZ2 SZ2 3.7 6 1.7 .0.05
FIG. 3. Association of FgRIIA and GP Iba on the platelet mem-
brane: fluorescence energy transfer analysis. Energy transfer ef-
ficiency was measured between FITC-conjugated and Cy3-conjugated
monoclonal antibodies bound to epitopes on the platelet membrane.
Results from a representative experiment are displayed as frequency
distribution curves. No energy transfer was detected between FITC-
IV.3 and Cy3-IV.3 (negative control, curve A). Energy transfer was
clearly seen between FITC-SZ2 and Cy3-AN51, two non-overlapping
epitopes on GP Iba (positive control, curve C). Intermediate levels of
energy transfer were observed between FITC-AN51 and Cy3-IV.3
(curve B).
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found that mAbs directed against GP Iba could significantly
reduce platelet binding by polymeric IgG and that these mAbs
inhibited binding by amounts comparable with those obtained
with the anti-FcgRII mAb IV.3. Because the GP Iba-specific
mAbs do not appear to bind FcgRIIA directly (data not shown),
these findings indicate that the above inhibitory activity re-
sults from steric hindrance, suggesting that FcgRIIA and GP
Iba are in close proximity on the platelet membrane.
We also demonstrated the proximity of these receptors more
directly by two methods, resonance energy transfer between
antibodies bound to FcgRIIA and GP Iba and co-immunopre-
cipitation experiments. Fluorophor-labeled antibodies bound to
the respective antigens were able to transfer emission energy
from the FITC-labeled antibody to the Cy3-labeled antibody,
regardless of whether the donor dye was associated with
FcgRIIA or GP Iba. The detection of energy transfer between
epitopes on FcgRIIA and GP Iba indicates that these receptors
are within 10 nm of each other. This proximity cannot be
explained by the random co-localization of FcgRIIA and GP
Iba. Indeed, we observed no homoassociative energy transfer
for epitopes on either receptor, indicating that the densities of
FcgRIIA and GP Iba on the platelet membrane are too low to
randomly produce FET. Our calculations of receptor density
also argue against the association being due to random distri-
bution. Based on previous estimates of platelet surface area
(20–80 mm2) (8) and receptor number (25,000 and 500–8,000
copies/platelet for GP Iba (1, 17) and FcgRIIA (2, 22), respec-
tively), and assuming random receptor distribution, the pre-
dicted distance between these receptors would exceed the lim-
its of detectable FET. Thus, the observed FET in our studies
indicates nonrandom association between FcgRIIA and GP Iba.
We obtained further evidence for a direct physical associa-
tion between the GP Ib-IX-V complex and FcgRIIA in our
platelet in immunoprecipitation studies. Using mAb IV.3, GP
Iba was invariably coprecipitated with FcgRIIA from platelet
membranes that had been pretreated with DTSSP, a chemical
cross-linking reagent that is membrane-impermeable (23). In
the absence of this pretreatment, the GP Iba was still recov-
ered, but the yield and frequency of recovery varied consider-
ably. These findings indicate that there is a direct interaction
between the GP Ib-IX complex and FcgRIIA, although the
interaction is weak enough to be disrupted under certain con-
ditions of lysis. Moreover, our ability to chemically cross-link
these receptors on the surface of intact platelets provides ad-
ditional evidence for their proximity.
Of note, platelet aggregation by streptococci was also blocked
by mAbs to GP Iba. In addition to providing corroborative data
for the aggregation studies using polymeric IgG, these results
may clarify some inconsistent findings on the mechanisms of
platelet aggregation by these organisms. Our previous studies
had demonstrated that platelet aggregation by many strains
was mediated by FcgRIIA (11, 14). A subsequent report, how-
ever, indicated that mAbs to GP Iba could inhibit platelet
aggregation by viridans group streptococci, suggesting a role
for this receptor (24). Although these divergent observations
may reflect different mechanisms of platelet activation used by
different species, our current data suggest that the inhibitory
activity observed by Ford et al. (24) is due to steric blockade of
FcgRIIA by the anti-GP Ib antibodies.
What are the potential consequences of the association be-
tween the GP Ib-IX-V complex and FcgRIIA? As yet no defini-
tive information exists to answer this question, but one possible
reason for their association may be for participation in signal
transduction. The interaction between the GP Ib-IX-V complex
and von Willebrand factor leads to signal transduction across
the platelet membrane, resulting in tyrosine phosphorylation
of a number of proteins and an influx of calcium (25–27). As yet,
the mechanism for this signal transduction has not been delin-
eated, and in particular it is unclear as to how the GP Ib-IX-V
complex is coupled to the signal transduction machinery. Its
subunits do not have tyrosine kinase activity, are not known to
bind to G-proteins, and are not phosphorylated by tyrosine
kinases. Recently, one of the 14–3-3 proteins has been shown to
associate with the GP Ib-IX-V complex (28, 29), but as yet no
clear mechanism has been proposed for how this association is
involved in signal transduction. The association of FcgRIIA
with the complex may provide a mechanism for signal trans-
duction by the complex. FcgRIIA is able to transduce activation
signals when cross-linked by aggregated IgG or IgG bound to
bacteria, as we have demonstrated here. This activation is
partly mediated by an interaction of an immune tyrosine-based
activation motif (ITAM) in the cytoplasmic domain of FcgRIIA
and the SH2 motif containing kinase Syk, a member of the Src
family of tyrosine kinases (30, 31). Recent evidence indicates
that the GP Ib-IX-V complex must be cross-linked to transmit
signals (32), a mechanism similar to that employed by FcgRIIA
for signal transmission (31). Thus, if an agonist is able to
change the conformation of the GP Ib-IX-V complex such that
subcomponents of the complex are brought together, this action
may also bring together and cross-link associated FcgRIIA
polypeptides, resulting in signal transduction.
Acknowledgments—We thank Martin Bigos and Richard Stoval of
Stanford University for valuable help with the FET studies and Mar-
garet Chambers and David A. Smith for excellent technical assistance.
REFERENCES
1. Lo´pez, J. A. (1994) Blood Coagul. Fibrinolysis 5, 97–119
2. Anderson, C. L., Chacko, G. W., Osborne, J. M., and Brandt, J. T. (1995) Semin.
Thromb. Hemostasis 21, 1–9
3. Moore, A., Ross, G. D., and Nachman, R. L. (1978) J. Clin. Invest. 62,
1053–1060
4. Chong, B. H., Fawaz, I., Chesterman, C. N., and Berndt, M. C. (1989) Br. J.
Haematol. 73, 235–240
5. Adelman, B., Sobel, M., Fujimura, Y., Ruggeri, Z. M., and Zimmerman, T. S.
(1989) J. Lab. Clin. Med. 113, 204–210
6. Rosenfeld, S. I., Looney, R. J., Leddy, J. P., Phipps, D. C., Abraham, G. N., and
Anderson, C. L. (1985) J. Clin. Invest. 76, 2317–2322
7. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H.,
Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk,
D. C. (1985) Anal. Biochem. 150, 76–85
8. Karas, S. P., Rosse, W. F., and Kurlander, R. J. (1982) Blood 60, 1277–1282
9. Harlow, E., and Lane, D. (1988) Antibodies: A Laboratory Manual, Cold Spring
Harbor Laboratory, Cold Spring Harbor, NY
10. Tron, L., Szollosi, J., Damjanovich, S., Helliwell, S. H., Arndt-Jovin, D. J., and
Jovin, T. M. (1984) Biophys. J. 45, 939–946
11. Sullam, P. M., Valone, F. H., and Mills, J. (1987) Infect. Immun. 55, 1743–1750
12. Corash, L. (1990) Blood Cells 16, 97–108
13. Becker, R. C., Tracy, R. P., Bovill, E. G., Mann, K. G., and Ault, K. (1994)
Coronary Artery Dis. 5, 339–345
14. Sullam, P. M., Jarvis, G. A., and Valone, F. H. (1988) Infect. Immun. 56,
2907–2911
15. Szollosi, J., Tron, L., Damjanovich, S., Helliwell, S. H., Arndt-Jovin, D., and
Jovin, T. M. (1984) Cytometry 5, 210–216
16. Szollosi, J., Damjanovich, S., Goldman, C. K., Fulwyler, M. J., Aszalos, A. A.,
FIG. 4. Co-immunoprecipitation of GP Ia with FcgRIIA from
digitonin-lysed platelets. Shown is an immunoblot with the anti-GP
Iba mAb WM23. The left lane is a control from a lysate of whole
platelets. The subsequent lanes are immunoprecipitates from the ly-
sates using antibodies against the polypeptides indicated (aFcgRII,
mAb IV.3; aGP V, mAb SW16; aGP Iba, mAb AK2). The lanes contain-
ing samples from platelets that had been chemically cross-linked with
DTSSP before immunoprecipitation are denoted above the blot.
Proximity of GP Iba and FcgRIIA on the Platelet Membrane 5335
 by on M









Goldstein, G., Rao, P., Talle, M. A., and Waldmann, T. A. (1987) Proc. Natl.
Acad. Sci. U. S. A. 84, 7246–7250
17. Koksch, M., Rothe, G., Kiefel, V., and Schmitz, G. (1995) J. Immunol. Methods
187, 53–67
18. Matyus, L. (1992) J. Photochem. Photobiol. B 12, 323–337
19. Liegler, T., Szollosi, J., Hyun, W., and Goodenow, R. S. (1991) Proc. Natl. Acad.
Sci. U. S. A. 88, 6755–6759
20. Bene, L., Balazs, M., Matko, J., Most, J., Dierich, M. P., Szollosi, J., and
Damjanovich, S. (1994) Eur. J. Immunol. 24, 2115–2123
21. Ford, I., Douglas, C. W., Cox, D., Rees, D. G., Heath, J., and Preston, F. E.
(1997) Br. J. Haematol. 97, 737–746
22. Tomiyama, Y., Kunicki, T. J., Zipf, T. F., Ford, S. B., and Aster, R. H. (1992)
Blood 80, 2261–2268
23. Jung, S. M., and Moroi, M. (1983) Biochim. Biophys. Acta 761, 152–162
24. Ford, I., Douglas, C. W., Preston, F. E., Lawless, A., and Hampton, K. K. (1993)
Br. J. Haematol. 84, 95–100
25. Kroll, M. H., Harris, T. S., Moake, J. L., Handin, R. I., and Schafer, A. I. (1991)
J. Clin. Invest. 88, 1568–1573
26. Oda, A., Yokoyama, K., Murata, M., Tokuhira, M., Nakamura, K., Handa, M.,
Watanabe, K., and Ikeda, Y. (1995) Thromb. Haemostasis 74, 736–742
27. Razdan, K., Hellums, J. D., and Kroll, M. H. (1994) Biochem. J. 302, 681–686
28. Du, X., Harris, S. J., Tetaz, T. J., Ginsberg, M. H., and Berndt, M. C. (1994)
J. Biol. Chem. 269, 18287–18290
29. Du, X., Fox, J. E., and Pei, S. (1996) J. Biol. Chem. 271, 7362–7367
30. Chacko, G. W., Brandt, J. T., Coggeshall, K. M., and Anderson, C. L. (1996)
J. Biol. Chem. 271, 10775–10781
31. Yanaga, F., Poole, A., Asselin, J., Blake, R., Schieven, G. L., Clark, E. A., Law,
C. L., and Watson, S. P. (1995) Biochem. J. 311, 471–478
32. Andrews, R. K., Kroll, M. H., Ward, C. M., Rose, J. W., Scarborough, R. M.,
Smith, A. I., Lopez, J. A., and Berndt, M. C. (1996) Biochemistry 35,
12629–12639
Proximity of GP Iba and FcgRIIA on the Platelet Membrane5336
 by on M
arch 23, 2009 
w
w
w
.jbc.org
D
ow
nloaded from
 
